Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Liraglutide vs Tirzepatide

Q: What is the difference between Liraglutide and Tirzepatide?

Liraglutide is a GLP-1 compound (Subcutaneous route) - Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Tirzepatide is a GLP-1 compound (Subcutaneous route) - Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

Q: Which has a longer half-life, Liraglutide or Tirzepatide?

Tirzepatide has the longest published plasma half-life (~5.0 days (120 h)), compared with Liraglutide (13 h).

Q: How often is each compound dosed in the research literature?

Liraglutide: once daily at a published dose range of 0.6–3 mg; Tirzepatide: once weekly at a published dose range of 2.5–15 mg. These are descriptive reference parameters, not dosing recommendations.

Q: Can you buy Liraglutide and Tirzepatide for research use?

Yes - Tirzepatide is available from New-U Research Compounds as lab-verified (>99% HPLC) compound.

Published pharmacokinetic and receptor-characteristic comparison with primary-source references.

Updated August 2026 Research use only

LIRAGLUTIDE

Liraglutide

GLP-1

GLP-1R

GLP1-RC-TZ

Tirzepatide

Dual receptor agonist

GLP-1R · GIPR

Key research differences

Liraglutide Tirzepatide Receptor profile GLP-1R GLP-1R · GIPR Development status Approved therapeutic molecule Approved therapeutic molecule Published half-life 13 h ~5.0 days (120 h) Research distinction Shorter-acting GLP-1R agonism Dual incretin agonism

Published research parameters

Liraglutide Saxenda, Victoza Tirzepatide Mounjaro, Zepbound View Tirzepatide → Receptor profile GLP-1R GLP-1R · GIPR Class GLP-1 Dual receptor agonist Plasma half-life 13 h ~5.0 days (120 h) Time to Cmax 11 h 36 h Development status Approved therapeutic molecule Approved therapeutic molecule Study context Regulatory label PK Regulatory label PK Primary publications FDA Saxenda USPI — half-life ~13 h (2023) FDA Mounjaro USPI — half-life ~5 days (120 h) (2024) Summary Short-acting GLP-1 receptor agonist. Once-daily subcutaneous. Weekly dose escalation reduces nausea. Dual GIP / GLP-1 receptor agonist. Once-weekly subcutaneous. 20-week titration is the FDA-label maximum-tolerated path.

View published study parameters

Liraglutide Saxenda, Victoza Tirzepatide Mounjaro, Zepbound View Tirzepatide → Route in published studies Subcutaneous Subcutaneous Published study interval Once daily Once weekly Published dose range 0.6–3 mg 2.5–15 mg Published study regimen 0.6 → 1.2 → 1.8 → 2.4 → 3 mg 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg

Source references

FDA Saxenda USPI — half-life ~13 h

FDA prescribing information · 2023

FDA Saxenda USPI — half-life ~13 h (2023)

Pi-Sunyer X et al.

New England Journal of Medicine · 2015

Pi-Sunyer X et al., NEJM 373:11 (2015)

FDA Mounjaro USPI — half-life ~5 days (120 h)

FDA prescribing information · 2024

FDA Mounjaro USPI — half-life ~5 days (120 h) (2024)

SURPASS-2 trial — NEJM 385:503

New England Journal of Medicine · 2021

SURPASS-2 trial — NEJM 385:503 (2021)

Urva S et al.

Clinical Pharmacokinetics · 2022

Urva S et al., Clin Pharmacokinet 61:1057 (Tmax 24–72 h) (2022)

Frequently asked questions

What is the difference between Liraglutide and Tirzepatide?

Which has a longer half-life, Liraglutide or Tirzepatide?

How often is each compound dosed in the research literature?

Can you buy Liraglutide and Tirzepatide for research use?

Continue researching

Research guides, current certificates and related research for Liraglutide and Tirzepatide. Research use only.

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Analytical evidence View the Tirzepatide COA Current batch purity and identity testing, 2026-05-27. View the COA →

Compare Compare Tirzepatide and Retatrutide Tirzepatide vs Retatrutide: mechanism, receptor profile and specifications side by side. Compare →

Continue research

← Compare other compounds

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research